首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1550543

全球慢性腎臟病藥物市場：依藥物類別、給藥途徑、適應症、通路及地區分類

Chronic Kidney Disease Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography

出版日期: 2024年08月13日 | 出版商:

Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球慢性腎臟病治療市場規模將達151億美元，2024年至2031年複合年成長率為5.2%，2031年將達215.5億美元。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	151億美元
實際資料	2019-2023	預測期	2024-2031
預測 2024-2031 年複合年成長率：	5.20%	2031 年金額預測	215.5億美元

圖：2024 年按地區分類的慢性腎臟病治療藥物市場佔有率（%）

全球慢性腎臟病藥物市場的成長是由全球腎臟病盛行率上升所推動的。慢性腎臟病（CKD）是指腎功能隨著時間的推移逐漸衰退。如果不及時治療，CKD 最終會導致腎衰竭和末期腎病變。 CKD 的常見原因包括糖尿病、高血壓、腎絲球腎炎和多囊性腎病變。人口老化的增加和文明病的增加可能導致 CKD 盛行率的增加。慢性腎臟病藥物旨在減緩疾病的進展、治療併發症並維持整體腎臟健康。腎素-血管收縮素系統抑制劑、鈣通道阻斷劑、紅血球生成刺激因子和利尿劑是用於治療慢性腎臟病的主要藥物類別。

市場動態：

全球慢性腎臟病藥物市場的成長是由糖尿病和高血壓盛行率上升所推動的。根據國際糖尿病聯盟發布的資料，2021年全球約有5.37億成年人將罹患糖尿病。預計到 2030 年，這一數字將增至 6.43 億，到 2045 年將增至 7.83 億。高血壓也是 CKD 的一個主要原因。政府積極努力提高人們對腎臟疾病早期診斷和治療的認知，這可能會推動市場成長。然而，新藥認證的嚴格規定以及與長期治療相關的嚴重副作用的風險可能會阻礙市場成長。聯合治療和標靶治療的開發為慢性腎臟病藥物行業的製造商提供了利潤豐厚的機會。

本研究的主要特點

該報告對全球慢性腎臟病治療市場進行了詳細分析，包括以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球慢性腎臟病藥物市場的主要企業進行了分析。

本報告中的主要企業包括輝瑞公司、葛蘭素史克公司、羅氏公司、賽諾菲公司、Keryx Biopharmaceuticals、Kissei Pharmaceutical Co. Ltd.、阿斯特捷利康公司和梯瓦製藥工業有限公司。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球慢性腎臟病藥物市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球慢性腎臟病治療藥物市場的各種策略矩陣，將有助於相關人員做出決策。

AstraZeneca
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi
GlaxoSmithKline plc（GSK）
AbbVie Inc.
Keryx Biopharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Reata Pharmaceuticals, Inc.
Ardelyx, Inc.
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
Novartis AG
Johnson & Johnson
Astellas Pharma Inc.
Takeda Pharmaceutical Company Limited
Akebia Therapeutics, Inc.

第10章分析師建議

命運之輪
分析師觀點
一致的機會圖

第11章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI1713

Global chronic kidney disease drugs market is estimated to be valued at USD 15.10 Billion in 2024 and is expected to reach USD 21.55 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 15.10 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	5.20%	2031 Value Projection:	US$ 21.55 Bn

Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2024

Chronic Kidney Disease Drugs Market - IMG1

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

By Drug Class
- ACE Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- B-Blockers
- Calcium Channel Blockers
- Loop Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Others
By Route of Administration:
- Oral
- Parenteral
By Indication
- Diabetic Nephropathy
- Glomerulonephritis
- Hypertensive Nephropathy
- Polycystic Kidney Disease
- Other Indications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Players Insights
- AstraZeneca
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Sanofi
- GlaxoSmithKline plc (GSK)
- AbbVie Inc.
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Akebia Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Chronic Kidney Disease Drugs Market, By Drug Class
- Global Chronic Kidney Disease Drugs Market, By Route of Administration
- Global Chronic Kidney Disease Drugs Market, By Indication
- Global Chronic Kidney Disease Drugs Market, By Distribution Channel
- Global Chronic Kidney Disease Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Angiotensin Receptor Blockers (ARBs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
B-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Loop Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Erythropoiesis-Stimulating Agents (ESAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phosphate Binders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Parentral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Kidney Disease Drugs Market, By Indication, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Diabetic Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Glomerulonephritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Hypertensive Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Polycystic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Kidney Disease Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, (USD Bn)
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi
GlaxoSmithKline plc (GSK)
AbbVie Inc.
Keryx Biopharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Reata Pharmaceuticals, Inc.
Ardelyx, Inc.
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
Novartis AG
Johnson & Johnson
Astellas Pharma Inc.
Takeda Pharmaceutical Company Limited
Akebia Therapeutics, Inc.